Brief: Shanghai Henlius Biotech's New Drug Application Of Innovative Small Molecular Hlx99 Approved By U.S. FDA
10/02/2025 10:21
Feb 10 (Reuters) - Shanghai Henlius Biotech Inc
2696.HK :
* CO'S NEW DRUG APPLICATION OF INNOVATIVE SMALL MOLECULAR
HLX99
("HLX99") WAS APPROVED BY U.S. FDA
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln